The increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Tyler Beardslee, PharmD, BCOP
Advertisement
Articles by Tyler Beardslee, PharmD, BCOP
Advertisement
Latest Updated Articles
Management of Steroid-Refractory Immune-Related Adverse EventsPublished: August 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?
3
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer
4
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
5
